Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Natriuretic factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Natriuretic factor. Displaying page 1 of 1.
    EudraCT Number: 2005-005083-81 Sponsor Protocol Number: ALBUCARD Start Date*: 2006-06-09
    Sponsor Name:HOSPITAL CLINIC
    Full Title: EFECTOS DE LA ADMINISTRACIÓN DE ALBÚMINA INTRAVENOSA SOBRE LA FUNCIÓN DIASTÓLICA DE LOS PACIENTES CON CIRROSIS HEPÁTICA.
    Medical condition: Liver cirrhosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003818-24 Sponsor Protocol Number: DC2015RED01 Start Date*: 2015-12-11
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked trans...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002928-53 Sponsor Protocol Number: HBT-GCP-PTCL-01 Start Date*: 2015-11-16
    Sponsor Name:The Heartbeat Trust
    Full Title: Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE)
    Medical condition: Patients (asymptomatic) with cardiovascular risk factors for heart failure including either hypertension and/or type II diabetes, with elevated levels of natriuretic peptide (brain natriuretic pept...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001547-12 Sponsor Protocol Number: DC2017RACELINES01 Start Date*: 2017-12-21
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002650-48 Sponsor Protocol Number: UCDCRC/22/02 Start Date*: 2023-05-05
    Sponsor Name:University College Dublin
    Full Title: The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study)
    Medical condition: pre-heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002645-38 Sponsor Protocol Number: BIOMARCHA Start Date*: 2012-09-04
    Sponsor Name:CRESIB-Barcelona Centre for International Health Research
    Full Title: Evolution of serologic biomarkers and diastolic function and segmentary contractility determined by echocardiography after treatment in Chagas diseases
    Medical condition: The study will be held in 63 patients with chronic Chagas Disease and 63 healthy people
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004999-19 Sponsor Protocol Number: 191001 Start Date*: 2020-06-16
    Sponsor Name:Department of infectious diseases, Hvidovre Hospital
    Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress...
    Medical condition: Human immunodeficiency viruses (HIV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10067326 Antiretroviral therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001626-26 Sponsor Protocol Number: OMT28-C0201 Start Date*: 2019-01-23
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (...
    Medical condition: Persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-005567-33 Sponsor Protocol Number: MEIN/14/FEB-PWV/001 Start Date*: 2015-09-11
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Tr...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001157-48 Sponsor Protocol Number: 20HH5896 Start Date*: 2020-07-28
    Sponsor Name:Imperial College London
    Full Title: Identifying a safe and tolerated dose of Imatinib for patients with Pulmonary Arterial Hypertension (PAH)
    Medical condition: Pulmonary Arterial Hypertension (Idiopathic, heritable, or assosicated with anorexigens)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036727 Primary pulmonary hypertension LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068739 Chronic thromboembolic pulmonary hypertension LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10050701 Congenital pulmonary hypertension PT
    20.0 10010331 - Congenital, familial and genetic disorders 10050701 Congenital pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003691-19 Sponsor Protocol Number: 2007-003691-19 Start Date*: 2008-01-25
    Sponsor Name:Dept of Molecular Medicin and Surgery
    Full Title: Tillskott av vitamin D efter framgångsrik operation för primär hyperparatyreoidism (pHPT) - prospektiv randomiserad dubbelblind studie
    Medical condition: Effekt av D-vitaminsubstitution efter framgångsrik operation för primär hyperparatyreoidism (pHPT)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001371-37 Sponsor Protocol Number: GDM-TREAT Start Date*: 2012-07-10
    Sponsor Name:Dr. med. Tina Vilsbøll
    Full Title: The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus
    Medical condition: Gestational diabetes mellitus Non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10018210 Gestational diabetes mellitus LLT
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003180-35 Sponsor Protocol Number: R04725 Start Date*: 2018-06-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Feasibility study on the effects of postnatal enalapril on maternal cardiovascular function following preterm pre-eclampsia
    Medical condition: Postnatal (PN) cardiovascular dysfunction following preterm pre-eclampsia (pPE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10040444 Severe pre-eclampsia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003497-48 Sponsor Protocol Number: EMPATHY Start Date*: 2021-11-29
    Sponsor Name:Medical University of Warsaw
    Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-005030-38 Sponsor Protocol Number: PAT-CR-302 Start Date*: 2019-08-10
    Sponsor Name:Vifor Pharma, Inc.
    Full Title: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone Syst...
    Medical condition: Management of hyperkalemia due to renin-angiotension-aldosterone system medications in patients treated for heart failure.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10005725 Blood potassium increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) NL (Completed) ES (Ongoing) HU (Completed) DE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000916-75 Sponsor Protocol Number: REC-DUT-002 Start Date*: 2018-06-07
    Sponsor Name:RECARDIO Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
    Medical condition: Acute myocardial infarction, acute myocardial ischemia, STEMI ST elevation myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) BE (Completed) NL (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 20:24:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA